Background {#Sec1}
==========

According to the guidelines of chronic obstructive pulmonary disease (COPD) management, inhaled corticosteroids (ICS) should be prescribed only to patients with a severe or very severe disease (stage 3 or 4), as assessed by a forced expiratory volume in 1 s (FEV1) lower than 50% of the predicted value or by frequent (more than 2/year) exacerbations \[[@CR1]\]. In recent years, an increasing number of reports disclosed that in COPD patients treated with ICS, there was a higher risk of developing pneumonia \[[@CR2], [@CR3]\]. Systematic reviews and meta-analyses confirmed the significantly higher risk of pneumonia in ICS-treated COPD patients compared with non-ICS treated patients; no significant effect on the mortality rate was detected \[[@CR4]--[@CR7]\].

In a meta-analysis, a 12-month budesonide treatment did not increase the risk of pneumonia \[[@CR5]\]. According to a review, "the immunosuppressive effects of ICS on the respiratory epithelium and the disruption of the lung microbiome are most likely to be implicated", and the conventional ICS doses are most likely too high \[[@CR8]\]. In a UK cohort of 23,013 COPD patients, it was reported that there was a greater risk of pneumonia in patients receiving higher ICS doses \[[@CR9]\]. In the same study, based on the lower risk of pneumonia observed in patients treated with extra-fine particle ICS compared with those treated with fine-particle ICS \[[@CR9]\], it was suggested that the kind of the inhalant preparation administered could possibly influence the risk of pneumonia. Thus far, no such studies have been conducted on COPD patients treated with ICS and undergoing pulmonary rehabilitation (PR). This treatment consists of a multidisciplinary care program individually tailored and designed for patients with chronic respiratory impairment in order to optimize physical and social performance and autonomy \[[@CR10]\]. PR was shown to reduce COPD exacerbations, often related to respiratory infections, by targeting risk factors such as physical inactivity, decreased exercise capacity and impaired physical functions \[[@CR11]\]. This study, carried out in 2016, was conceived to evaluate the incidence of pneumonia in a cohort of COPD patients undergoing PR and treated with ICS or bronchodilators as compared to a control group not treated with PR.

Methods {#Sec2}
=======

The study prospectively evaluated a cohort of COPD patients undergoing PR based on the insufficient control of the disease despite appropriate drug treatment \[[@CR10]\]. To be admitted to the PR program, patients must have a FEV1 lower than 80% of the predicted, as measured by spirometry. Patients were divided in three groups: the first group included PR patients treated with ICS; the second group included PR patients treated only by bronchodilators; and, the third group included non-PR patients treated with ICS. For all COPD patients, the level of exercise capacity was measured by a 6-min walking test \[[@CR12]\] A further group of ICS-treated patients with asthma and a low risk of pneumonia, as shown by a meta-analysis of available randomized trials \[[@CR13]\], served as a control group.

In 2016, all PR patients underwent four or 6-month interval rehabilitative treatments depending on the severity of the disease. PR was performed as previously described \[[@CR14]\]. The program, based on a schedule of 12 sessions within a 6-week period, involved exercise training on a cycle-ergometer or treadmill, upper-limb and trunk exercises, respiratory muscle training, and COPD education. Patients were instructed to contact the attending nurse in case of any important health-related events. When symptoms or signs of pneumonia were detected by the general practitioner or the ED physician, the diagnosis of pneumonia had to be confirmed with a chest x-ray.

Statistical analysis {#Sec3}
--------------------

Differences in incidence of pneumonia were analyzed by the Chi squared test, a p value lower that 0.05 being regarded as positive.

Results {#Sec4}
=======

The cohort study included 438 COPD patients undergoing PR, of which 353 were treated with ICS or ICS-LABA combinations, and 85 patients were treated only with bronchodilators. Of those patients treated with ICS, 246 received fluticasone/salmeterol; 64 beclomethasone/formoterol, 26 budesonide/formoterol, 8 fluticasone/vilanterol, 4 fluticasone, and 5 ciclesonide. The group of COPD patients not receiving PR included 76 subjects treated with ICS or ICS-LABA combinations of which 42 received fluticasone/salmeterol, 16 beclomethasone/formoterol, 11 budesonide/formoterol, 5 fluticasone/vilanterol, 1 beclomethasone/formoterol, and 1 fluticasone. The control group of patients with asthma included 49 subjects of which 13 received fluticasone/salmeterol, 12 beclomethasone/formoterol, 12 budesonide/formoterol, 6 fluticasone/vilanterol, 3 fluticasone/formoterol, 2 budesonide and 1 ciclesonide. The initial pharmacological regimen was maintained throughout the study. The patients treated with ICS only were given this prescription because the spirometric values were near to normality, but had frequent exacerbations. Table [1](#Tab1){ref-type="table"} shows the demographic characteristics of the various groups of patients as well as the mean values of FEV1 and the 6-min walking test. Overall, in 2016, 6 cases of pneumonia (only one requiring hospitalization) were diagnosed in the cohort of patients undergoing PR, 5 in ICS treated patients, and 1 in patients treated only with bronchodilators, corresponding to a rate of 1.41 and 1.17%, respectively. The difference in the rates was not significant. In particular, among the ICS-treated patients with pneumonia, 4 were treated with fluticasone/salmeterol, and 1 with budesonide/formoterol, also this difference being not significant. In the COPD group not receiving PR, 5 cases of pneumonia (none requiring hospitalization) were diagnosed, which corresponded to a rate of 6.6%. Of the 5 patients with pneumonia, 3 were treated with fluticasone/salmeterol, 1 with beclomethasone/formoterol and 1 with budesonide/formoterol. A significant difference (p = 0.029) was detected comparing the number of patients with pneumonia in the study group vs. the number of patients with pneumonia in the control group not receiving PR. No case of pneumonia was registered in the control group of patients with asthma.Table 1Demographic data and functional values from the different groups of patientsGroupGenderMean age (years)Mean FEV1 value (% predicted)Mean 6-min walking testCOPD patients undergoing PR303 males, 135 females73.656.1353.9COPD patients on PR treated with ICS234 males, 119 females74.752.7327.3COPD patients on PR treated only with bronchodilators69 males, 16 females72.959.6380.7COPD patients not on PR treated with ICS47 males, 29 females71.554.2358.4Asthmatic patients treated with ICS28 males, 21 females54.771.5N.A.

Discussion and conclusions {#Sec5}
==========================

There is clear evidence in the literature that the use of ICS in COPD patients increases the risk of pneumonia \[[@CR4]--[@CR7]\]. Based on this observation, the updated GOLD Guidelines recommend that ICS be prescribed only to patients with severe or very severe (GOLD 3 or 4) disease \[[@CR15]\]. When the treatment is required, individuating the minimal effective dose of ICS in these patients will likely lessen the risk of pneumonia \[[@CR16]\]. Our study suggests that PR may substantially reduce such risk (Fig. [1](#Fig1){ref-type="fig"}). In fact, our findings show that in ICS treated-patients undergoing PR the incidence of pneumonia was 1.41%. There was no significant difference in PR patients treated with bronchodilators compared to patients treated with ICS, instead the difference in rate was found to be significant in the cohort of patients treated with ICS but not with PR. We also compared the reported incidence of pneumonia in COPD patients, treated with or without ICS, and in the general population. The figures for COPD patients were obtained from the Cochrane meta-analysis of the risk of pneumonia stemming from ICS \[[@CR6]\], while those concerning the general population were taken from the literature review from Torres et al. \[[@CR17]\]. The available data are summarized in Table [2](#Tab2){ref-type="table"}. It is evident that the incidence of pneumonia in COPD patients treated with ICS undergoing PR is significantly higher than the general population (p \< 0.001), and significantly lower than COPD patients treated with fluticasone (p \< 0.001). Our data do not confirm the lower incidence of pneumonia in patients treated with budesonide compared with those treated with fluticasone, as reported in meta-analyses \[[@CR4], [@CR5]\] and population studies \[[@CR18]\], but the very low number of pneumonia in our study (5 and 1, respectively) cannot provide statistical reliability. The low number of pneumonia cases in both the study and control groups, related to the limited number of patients (\< 100), affected the comparison of pneumonia incidences according to the different ICS used. Fig. 1Study flowchart and grouping. *COPD* chronic obstructive pulmonary disease, *ICS* inhaled corticosteroids, *PR* pulmonary rehabilitationTable 2Pneumonia events in the general population, in COPD patients and in COPD patients treated with ICSGeneral population Torres et al. \[[@CR17]\]COPD patients Kew et al. \[[@CR6]\]COPD patients treated with fluticasone Kew et al. \[[@CR6]\]COPD patients treated with budesonide Kew et al. \[[@CR6]\]1.07--4.2 cases per 1000 person-year. In Italy 1.7 cases per 1000 person-yearControls in trials with fluticasone (follow-up 22 months): 72 per 1000 Controls in trials with budesonide (follow-up 10 months): 28 per 1000Follow-up 22 months: 116 per 1000Follow-up 10 months: 31 per 1000

According to a meta-analysis, PR has several potential benefits, e.g., relieving dyspnea and fatigue, improving exercise capacity, and health-related quality of life, thus enhancing the sense of control that individuals have over their condition. The authors stated that additional RCTs comparing pulmonary rehabilitation and conventional care in COPD are not warranted \[[@CR19]\]. Instead, studies on large populations of PR-treated patients are necessary to confirm our observation of reducing the risk of pneumonia by using ICS. On the other hand, a favorable clinical course was reported in hospitalized patients with severe COPD undergoing PR treatment affected by acquired pneumonia while in hospital (HAP) \[[@CR20]\]. The zero mortality rate mentioned is relevant, considering the substantial mortality due to HAP. The underlying factors of these outcomes of PR on pneumonia incidence could be possibly due to the beneficial effects of physical activity and patient education. Indeed, in a study on 441 adults undergoing upper abdominal surgery, patients were randomized to receive pre-operative physiotherapy and education (study group) or simply an information booklet (control group). The incidence of HAP was halved in the study group compared with the control group, with an absolute risk reduction of 15% \[[@CR21]\].

Also, the risk of pneumonia is affected by the extent of the subjects physical activity. In fact, in a large population of 109,352 runners and 40,798 walkers, higher doses of running and walking (with no difference between the two) were associated with a lower risk of pneumonia, and a mortality rate decrease of 13%. This outcome appeared to be independent of the effect of exercise on cardiovascular diseases \[[@CR22]\]. However, studies are needed to specifically address the incidence of pneumonia in active COPD patients according to the type and extent of their physical exercise. The absence of the risk of pneumonia in patients with asthma, which has been demonstrated by a meta-analysis \[[@CR13]\], although a significant reduction in physical activity has been reported in patients with severe asthma \[[@CR23]\], warrants further investigation.

COPD

:   chronic obstructive pulmonary disease

FEV1

:   forced expiratory volume in 1 s

HAP

:   hospital acquired pneumonia

ICS

:   inhaled corticosteroids

PR

:   pulmonary rehabilitation

ER, CI wrote and coordinated the draft of the manuscript. IM, FL, LL, GGRS, AB, BLG collected data, carried out the bibliographic search, contributed to the draft of the manuscript and made substantial contribution to the revision of the article. LP revised the final draft of the manuscript. All authors read and approved the final manuscript.

Acknowledgements {#FPar1}
================

The authors thank Mrs Elisabeth Stabler for language revision.

Competing interests {#FPar2}
===================

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials {#FPar3}
==================================

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication {#FPar4}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar5}
==========================================

All patients signed informed consent.

Funding {#FPar6}
=======

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
